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June Supplement 201160S Abstractsoverestimated it. The expenditure of DUAM is lower than
both DSA and MRA.
Of 421procedures based on DUAM, immediate clini-
cal improvement was comparable between EvR and BS,
with improvement to Rutherford category 3 or less 98% in
EvR and 97% in BS (P0.71). 6-year freedom from binary
re-stenosis was 72.8% EvR and 65.3% BS (P0.7001,
hr1.10, 95% CI  [0.69 to 1.74]). 6-year Amputation
Free Survival was 72.9% EvR and 71.2% BS (P0.9765,
hr0.95, 95% CI  [0.60 to 1.51]).
Comparing procedures performed based on DUAM to
those based on MRA, 6-year binary re-stenosis was 69% for
DUAM procedures Vs 57% for MRA procedures (P0.02,
hr0.255, 95% CI  [0.09-0.71]).
Conclusions: DUAM is an outstanding pre-operative
imaging tool and epitomizes a minimally invasive modality
to road-map EvR for CLI and offers precise consecutive
data with hemodynamic outcome and limb salvage superior
to EvR based onMRA.We believe that DUAM is econom-
ically proficient, primary modality for managing patients
with CLI.
Author Disclosures: S. Sultan: Nothing to disclose; W.
Tawfick: Nothing to disclose.
PS116.
Our Experience with Laser Angioplasty of 258 Lower
Extremities: Statin Use Improves Patency
Jung Kim, Sadaf S. Ahanchi, Jarrod Day, Brian Chen,
Babatunde Almaroof, Megan Caroll, Jean Panneton. East-
ern Virginia Medical School, Norfolk, VA
Objectives:The literature on atherectomy is difficult to
interpret due to a lack of uniform reporting standards. Our
objective was to review our experience with laser atherec-
tomy and assess factors affecting patency.
Methods: We conducted a retrospective chart review
of all laser atherectomies from January 1st, 2006 to May
31st, 2010. Periprocedural data was obtained from elec-
tronic medical records and subgroup analysis of isolated
superficial femoral artery (SFA) atherectomy was
completed.
Results: Laser atherectomy was performed on 258
limbs in patients with a mean age of 70. The procedural
indication was claudication (51%) or critical limb ischemia
(49%). Laser atherectomy was performed as a stand-
alone procedure in 6%, with percutaneous transluminal
angioplasty (PTA) in 73%, or with PTA/stenting in 22%.
Arterial location was iliac/common femoral (2%), SFA/
popliteal (66%), infrapopliteal (15%), or other (18%). Of
293 treated segments, 62.5% were occlusive and 37.5%
were stenotic.
Overall primary patency rates at 1 and 3 years were 48%
and 36%. Overall limb salvage rate for CLI limbs (130
limbs) was 93% at 1 year and 88% at 3 years. There was no
significant difference between the statin (120 patients) eersus non-statin group (114 patients) for any demo-
raphic variables. The 1 and 3 year primary patency rates
ere significantly different between statin (57%, 45%) ver-
us non-statin group (39%, 26%) (adjusted hazard ratio,
.54; p0.01).
Subgroup analysis of the isolated SFA interventions
howed a significant difference in primary patency in favor
f native versus in-stent arteries (p0.01).
Conclusions: Laser atherectomy was mostly used in
ombination with PTA with acceptable patency and satis-
actory limb salvage rate in CLI patients., The use of statins
ignificantly improves primary patency after laser
ngioplasty.
uthor Disclosures: S. S. Ahanchi: Nothing to disclose;
. Almaroof: Nothing to disclose; M. Caroll: Nothing to
isclose; B. Chen: Nothing to disclose; J. Day: Nothing to
isclose; J. Kim: Nothing to disclose; J. Panneton: Noth-
ng to disclose.
S118.
orbidity of Prosthetic Graft Infections
effrey J. Siracuse, Marc L. Schermerhorn, Prathima Nan-
ivada, Kristina A. Giles, Allen D. Hamdan, David R.
ampbell, Mark C. Wyers, Elliot L. Chaikof, Frank B.
omposelli. Surgery, Beth Israel Deaconess Medical Cen-
er and Harvard Medical School, Boston, MA
Objectives: Prosthetic graft infection is a major and
eared complication of peripheral vascular surgery. We set
orth to investigate our institution’s experience with these
or arterial bypasses involving the femoral artery.
Methods: A retrospective cohort single institution re-
iew of prosthetic bypass grafts involving the femoral artery
rom 2005-2010 looked at patient demographics, BMI,
omorbidities, indications, location of bypass, type of pros-
hetic material, case urgency, previous ipsilateral bypasses
r percutaneous interventions, and evaluated mortality,
mputations, graft infections.
Results: There were 255 prosthetic grafts identified.
he graft infection rate was 4.7% with a median time to
resentation of 90 days after bypass. Multivariate analysis
hows redo (23% redo vs. 77% primary) bypass as a signifi-
ant predictor of graft infection (OR 4.1, 95% CI 1.3-12.9,
0.05). Redo bypasses made up 56% of graft infections.
emale gender and diabetes trended towards significance as
isk factors (OR 3.0, 95%CI .9-10.2, p.076,OR 3.6, 95%
I .96-13.7, p.058). Graft infection was predictive of
ajor lower extremity amputation (HR 11.3, 95% 3.2-
0.1, p .001). There was no difference in mortality.
nfected grafts were removed 77% of the time. Methicillin-
ensitive S. aureus (42%) and S. epidermidis (33%) were the
ost common pathogens isolated.
Conclusions: Redo bypasses are at a higher risk for
raft infection and that can lead to a higher rate of major
xtremity amputation. Alternate sources of vein and endo-
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Volume 53, Number 17S Abstracts 61Svascular interventions should be used when available in
high risk patients.
Author Disclosures: D. R. Campbell: Nothing to disclose;
E. L. Chaikof: Nothing to disclose; K. A. Giles: Nothing to
disclose; A. D. Hamdan: Endologix,Consulting fees or
other remuneration (payment); P. Nandivada: Nothing to
disclose; F. B. Pomposelli: Nothing to disclose; M. L.
Schermerhorn: Boston Scientific,Consulting fees or other
remuneration (payment) Endologix,Consulting fees or
other remuneration (payment) Medtronic,Consulting fees or
other remuneration (payment); J. J. Siracuse: Nothing to
disclose; M. C. Wyers: Endologix,Consulting fees or other
remuneration (payment).
PS120.
Are Outcomes of Tibial Artery Atherectomy or Stent-
ing Superior to Tibial Angioplasty Alone Over Time in
the US Medicare Population?
Todd R. Vogel1, Viktor Y. Dombrovskiy1, Paul B. Haser1,
Jeffrey L. Carson2, Alan M. Graham1. 1Department of
Surgery, UMDNJ-Robert Wood Johnson Medical School,
New Brunswick, NJ; 2Department of Medicine, UMDNJ-
Robert Wood Johnson Medical School, New Brunswick, NJ
Objectives: Catheter-based revascularization for the
tibioperoneal vessels is increasingly performed for limb
salvage. Few data are available evaluating longitudinal
outcomes after tibioperoneal angioplasty alone com-
pared to adjunctive tibial procedures including stenting
and atherectomy.
Methods: Patients undergoing percutaneous tibioper-
oneal interventions with a diagnosis of ulceration were iden-
tified using The Centers for Medicare & Medicaid Services
inpatient claims (2005-2007). Patients were grouped: tib-
ioperoneal angioplasty only (TA); tibioperoneal angioplasty
plus stent placement (TAS); and tibioperoneal angioplasty
plus atherectomy (TAA). Complications and longitudinal
amputation rates were evaluated.
Results: 2,080 patients, with a mean age of
77.98.3 years (57.7% male; 79.1% White, 13.3% Black)
underwent tibioperoneal angioplasty for the indication
of ulceration. Procedures included: TA (56.3%), TAS
(16.2%); TAA (27.5%). Overall initial hospital compli-
cations were not significantly different among groups.
Rates of amputation are presented (See Table). Adjusted
for age, gender, race, procedure, and comorbidities, pre-
dictors of 30- and 90-day, and 1-year amputation were
male gender and diabetes. Mean total hospital charges
were: TA ($50,300), TAS ($65,680; P0.0001); TAA
($54,808; P0.057).
Conclusions: Patients undergoing tibioperoneal an-
gioplasty with concomitant stenting or atherectomy during
their initial intervention for ulceration incurred greater
hospital charges and demonstrated no improvement on
amputation rates over time compared to tibial angioplasty
alone. Future trials of adjunctive tibioperoneal intervention Ore essential to temper cost as they fail to improve long term
imb salvage.
ates of Any Amputation Over Time
rocedure
30-day
Amputation
Rate
90-day
Amputation
Rate
1 Year
Amputation
Rate
ibial Angioplasty
(TA) Alone
10.85% 18.79% 28.27%
A  Stent 9.52% 15.18% 24.70%
A  Atherectomy 9.08% 18.15% 28.10%
-Values
NSNon-
Significant
All Differences
NS
All Differences
NS
All Differences
NS
uthor Disclosures: J. L. Carson: Nothing to disclose;
. Y. Dombrovskiy: Nothing to disclose; A. M. Graham:
othing to disclose; P. B. Haser: Nothing to disclose;
. R. Vogel: American Heart Association,Research
rants.
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S122.
rosthetic Conduit is Equivalent to Alternative Vein
ources for Below-Knee Popliteal Bypass Targets in the
bsence of Single Segment Greater Saphenous Vein
ames T. McPhee, Neal R. Barshes, Louis L. Nguyen,
harles K. Ozaki, Michael Belkin. Vascular & Endovascu-
ar Surgery, Brigham & Women’s Hospital, Boston, MA
Objectives: Single segment greater saphenous vein
SSGSV) is the conduit of choice for femoral to below-knee
opliteal bypass (F-BKP). The purpose of this study was to
etermine the optimal conduit in patients with inadequate
SGSV.
Methods: This is a retrospective review of a prospec-
ively maintained vascular registry. Patients underwent F-
KP bypass with either alternative vein (AV) [arm vein/
pliced GSV/composite vein] or prosthetic conduit (PC)
or any indication.
Results: From 01/95-06/10, 85 patients had unus-
ble SSGSV for F-BKP reconstruction. 33 patients had AV
onduit (18.2% arm vein; 81.8% composite)and 52 patients
ad PC (80.8% PTFE, 13.5% Dacron, 1.9% composite and
.8% cryovein). The AV and PC groups had similar mean
ge (68 vs. 72.1, p.08),DM (57.6% vs. 57.7%,
.6),smoking (15.2% vs. 30.8%, p.08), CAD (57.6% vs.
7.3%, p.2), and CLI (93.9% vs. 86.5%, p.2). Most
ere primary bypass attempts for both AV and PC (90.9%
s. 84.6% p0.3). The CFA was the primary inflow for
oth (87.9% vs. 90.4%, p.5). AV and PC groups had
imilar 30 day mortality (3.0% vs. 1.9%, p.6) and major
orbidity (6.1% vs. 7.7%, p.6). PC patients were more
ikely to be placed on Coumadin (p.001). By five-year life
able analysis, there was no significant difference in terms of
rimary, assisted primary, secondary patency or limb sal-
age rates at mean follow up of 1087 and 665 days (Table).
f the 9 failed AV grafts, 7 had new bypass grafts created,
